Literature DB >> 17610546

RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia.

K Fischer1, D E Grobbee, H M van den Berg.   

Abstract

It has been suggested that more RCTs should be conducted in the evaluation of haemophilia treatment, including prophylaxis. To draw valid conclusions from experimental or observational studies, internal validity should be ensured. In particular, similarity of prognosis between treatment groups compared in a particular study is needed. Because the use of prophylaxis in observational studies is nonrandomized by definition, special efforts should be made to achieve comparability of prognosis, that is, to avoid 'confounding by indication'; in RCTs this is ensured by randomized allocation of treatment. However, the high costs of an RCT results in a limitation of both patient numbers and length of follow up. Observational studies tend to be more generalizable and cheaper, as they may include a wider spectrum of morbidities, use treatment protocols in agreement with routine care, and use available data. Therefore, observational studies can be much larger and of longer duration than RCTs; and are the preferred design for the evaluation of long term treatment effects. Several valid observational studies comparing prophylaxis and on demand treatment have reported both a short term reduction of 75-90% in bleeding frequency, and significant improvement in arthropathy, quality of life, and socioeconomic parameters after more than 20 years of prophylactic treatment. RCTs provide the most powerful tool for the evaluation of short term effects of any treatment, but are infeasible for the evaluation of long term effects. The definitive assessment of the long-term benefits of prophylaxis requires observational studies that should be performed according to rigorous standards.

Entities:  

Mesh:

Year:  2007        PMID: 17610546     DOI: 10.1111/j.1365-2516.2007.01521.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.

Authors:  Kathelijn Fischer; Maurice E Pouw; Daniel Lewandowski; Mart P Janssen; H Marijke van den Berg; Ben A van Hout
Journal:  Haematologica       Date:  2011-01-27       Impact factor: 9.941

2.  Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.

Authors:  Karin C Berger; Brian M Feldman; Joan Wasserman; Wolfgang Schramm; Victor Blanchette; Kathelijn Fischer
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

3.  Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Authors:  Kathelijn Fischer; Katarina Steen Carlsson; Pia Petrini; Margareta Holmström; Rolf Ljung; H Marijke van den Berg; Erik Berntorp
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

Review 4.  Primary prophylaxis in children with haemophilia.

Authors:  Antonio Coppola; Mirko Di Capua; Ciro De Simone
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

5.  Impact of prophylaxis on health-related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries.

Authors:  Koyo Usuba; Victoria E Price; Victor Blanchette; Audrey Abad; Carmen Altisent; Loretta Buchner-Daley; Jorge D A Carneiro; Brian M Feldman; Kathelijn Fischer; John Grainger; Susanne Holzhauer; Koon-Hung Luke; Sandrine Meunier; Margareth Ozelo; Ling Tang; Sandra V Antunes; Paula Villaça; Cindy Wakefield; Gilian Wharfe; Runhui Wu; Nancy L Young
Journal:  Res Pract Thromb Haemost       Date:  2019-04-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.